

**ACTION:** Notice.

**SUMMARY:** Findings of research misconduct have been made against Terry Magnuson, Ph.D. (Respondent), Kay M. & Van L. Weatherspoon Eminent Distinguished Professor, Department of Genetics, School of Medicine (SOM), University of North Carolina at Chapel Hill (UNC). Respondent engaged in research misconduct in research included in one (1) grant application for U.S. Public Health Service (PHS) funds, specifically National Cancer Institute (NCI), National Institutes of Health (NIH), grant application R01 CA267946–01A1. The administrative actions, including supervision from February 25, 2022–January 5, 2024, are detailed below.

**FOR FURTHER INFORMATION CONTACT:**

Wanda K. Jones, Dr.P.H., Acting Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 240, Rockville, MD 20852, (240) 453–8200.

**SUPPLEMENTARY INFORMATION:** Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

*Terry Magnuson, Ph.D., University of North Carolina at Chapel Hill:* Based on the report of an assessment conducted by UNC, Respondent's admission, and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Terry Magnuson, Kay M. & Van L. Weatherspoon Eminent Distinguished Professor, Department of Genetics, SOM, UNC, engaged in research misconduct in research included in one (1) grant application for PHS funds, specifically NCI, NIH, grant application R01 CA267946–01A1.

ORI found that Respondent engaged in research misconduct by intentionally, knowingly, or recklessly plagiarizing text from the following three (3) online articles and one (1) published paper:

- Comprehensive Guide to Understanding and Using CUT&Tag Assay. November 4, 2020. <https://www.activemotif.com/blog-cut-tag> (hereafter referred as “*Blog cut&tag 2020*”).
- Complete Guide to Understanding and Using ATAC-Seq. February 9, 2021. <https://www.activemotif.com/blog-atac-seq> (hereafter referred as “*Blog ATAC-Seq 2021*”).
- Illumina CATCH–IT. <https://www.illumina.com/science/sequencing-method-explorer/kits-and-arrays/catch-it.html> (hereafter referred as “*Illumina Catch-it*”).
- Modeling Physiological Events in 2D vs. 3D Cell Culture. *Physiology (Bethesda)* 2017 Jul;32(4):266–277; doi: 10.1152/physiol.00036.2016 (hereafter

referred as “*Physiology (Bethesda) 2017*”).

Plagiarized text was included in:

- Grant application R01 CA267946–01A1, “Genome-wide dynamics of chromatin modifiers,” submitted to NCI, NIH, on March 1, 2021 (hereafter referred as “R01 CA267946–01A1”)
- Specifically, ORI found that Respondent knowingly, intentionally, or recklessly plagiarized from:
  - The introduction (p. 266) and techniques (p. 267) sections of *Physiology (Bethesda) 2017* to compose subsection “ii. Identifying changes to SWI/SNF composition driven by cell state changes” of Specific Aim 1 of R01 CA267946–01A1
  - the introduction and sections “What is CUT&Tag” and “Before CUT&Tag, There Was CUT&RUN” of *Blog cut&tag 2020* to compose the “CHIP-seq protocols” description in R01 CA267946–01A1
  - the “What is ATAC-Seq?” section of *Blog ATAC-Seq 2021* to compose the “ATAC-seq protocols” description in R01 CA267946–01A1
  - the web page “*Illumina Catch-it*” describing the CATCH–IT technology to compose the “Pitfalls & Alternatives” section of Specific Aim 1 in R01 CA267946–01A1

Dr. Magnuson entered into a Voluntary Settlement Agreement (Agreement) and voluntarily agreed to the following:

(1) Respondent will have his research supervised from February 25, 2022–January 5, 2024 (the “Supervision Period”). Prior to the submission of an application for PHS support for a research project on which Respondent's participation is proposed and prior to Respondent's participation in any capacity in PHS-supported research, Respondent will submit a plan for supervision of Respondent's duties to ORI for approval. The supervision plan must be designed to ensure the integrity of Respondent's research. Respondent will not participate in any PHS-supported research until such a supervision plan is approved by ORI. Respondent will comply with the agreed-upon supervision plan.

(2) The requirements for Respondent's supervision plan are as follows:

- The respondent will submit his grant applications seeking PHS support to the Vice Dean, UNC SOM, thirty (30) days prior to the grant application submission deadline. The SOM Office of Research (OR) will review Respondent's grant applications to check for plagiarism and ensure compliance with acceptable scientific practice for citation

of prior work. SOM OR will not recruit Respondent's supervisor or collaborators to review his grant applications. SOM OR will submit a report to ORI at six (6) month intervals setting forth the committee meeting dates and Respondent's compliance with appropriate research standards and confirming the integrity of Respondent's research.

ii. SOM OR will conduct an advance review of any report, manuscript, or abstract involving PHS-supported research in which Respondent is involved. The review will include a discussion with Respondent of the primary data represented in those documents and will include a certification to ORI that the data presented and the text in the report, manuscript, or abstract is supported by the research record and not plagiarized.

(3) During the Supervision Period, Respondent will ensure that any institution employing him submits, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported and not plagiarized in the application, report, manuscript, or abstract.

(4) If no supervision plan is provided to ORI, Respondent will provide certification to ORI at the conclusion of the Supervision Period that his participation was not proposed on a research project for which an application for PHS support was submitted and that he has not participated in any capacity in PHS-supported research.

Dated: March 8, 2022.

**Wanda K. Jones,**

Acting Director, Office of Research Integrity,  
Office of the Assistant Secretary for Health.

[FR Doc. 2022–05217 Filed 3–10–22; 8:45 am]

**BILLING CODE 4150–31–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Impact of Health Misinformation in the Digital Information Environment in the United States Throughout the COVID–19 Pandemic Request for Information (RFI); Correction

**AGENCY:** Office of the Surgeon General, Department of Health and Human Services.

**ACTION:** Notice; correction.

**SUMMARY:** The Office of the Surgeon General published a document in the **Federal Register** of March 7, 2022, requesting information regarding the Impact of Health Information Misinformation in the Digital Information Environment in the United States Throughout the COVID-19 Pandemic. The document included a hyperlink in which the public will not be able to access.

**FOR FURTHER INFORMATION CONTACT:** Max Lesko at [COVIDMisinfoRFI@hhs.gov](mailto:COVIDMisinfoRFI@hhs.gov) or at (202) 893-5020.

#### **SUPPLEMENTARY INFORMATION:**

#### **Correction**

In the **Federal Register** of March 7, 2022, in FR Doc. 2022-04777, on page 12713, in the third column, correct the section which reads, "a. Starting with, but not limited to, *these common examples* of COVID-19 vaccine misinformation documented by the Centers for Disease Control and Prevention (CDC), any aggregate data and analysis on the prevalence of COVID-19 misinformation on individual platforms including exactly how many users saw or may have been exposed to instances of COVID-19 misinformation." to read, "a. Starting with but not limited to <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/facts.html> of COVID-19 vaccine misinformation documented by the Centers for Disease Control and Prevention (CDC), any aggregate data and analysis on the prevalence of COVID-19 misinformation on individual platforms including exactly how many users saw or may have been exposed to instances of COVID-19 misinformation."

**Max Lesko,**  
Chief of Staff, Office of the Surgeon General.  
[FR Doc. 2022-05132 Filed 3-10-22; 8:45 am]  
**BILLING CODE 4150-28-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose

confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; American Women: Assessing Risk Epidemiologically (AWARE) (R01 Clinical Trial Optional).

**Date:** April 5, 2022.

**Time:** 11:00 a.m. to 4:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22B, Rockville, MD 20892 (Virtual Meeting).

**Contact Person:** Kristina S. Wickham, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22B, Rockville, MD 20852, 301-761-5390, [kristina.wickham@nih.gov](mailto:kristina.wickham@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

**Dated:** March 7, 2022.

**Tyeshia M. Roberson-Curtis,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-05136 Filed 3-10-22; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; NIDDK Data Coordinating Center.

**Date:** April 5, 2022.

**Time:** 12:30 p.m. to 3:30 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health/NIDDK, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).

**Contact Person:** Elena Sanovich, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7351, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, 301-594-8886, [sanoviche@mail.nih.gov](mailto:sanoviche@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

**Dated:** March 7, 2022.

**Miguelina Perez,**

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-05135 Filed 3-10-22; 8:45 am]

**BILLING CODE 4140-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **Prospective Grant of an Exclusive Patent License: Development and Commercialization of Fusion Proteins for the Treatment of Growth Disorders and Diseases of Cartilage Degeneration**

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The *Eunice Kennedy Shriver* National Institute of Child Health and Human Development and the National Cancer Institute, both institutes of the National Institutes of Health, Department of Health and Human Services, are contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Cavalry Biosciences, Inc. of San Francisco, CA.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 28, 2022 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Richard T. Girards, Jr., Esq., MBA, Senior Technology Transfer Manager, National Institutes of Health,